Skip to main content
. Author manuscript; available in PMC: 2019 Mar 8.
Published in final edited form as: N Engl J Med. 2018 Mar 8;378(10):911–923. doi: 10.1056/NEJMoa1708131

Figure 1. Enrollment, Randomization, and Follow-up of the Participants.

Figure 1

Other reasons for exclusion from the trial included the following: had an infant with a gestational age of more than 28 weeks at the screening or enrollment visit; planned to be followed at a nontrial site; did not return after screening visit; was younger than 18 years of age; had a positive test for hepatitis C virus or the human immunodeficiency virus; terminated the pregnancy; had a delivery, miscarriage, fetal death, or molar pregnancy; was receiving antiviral agents; had proteinuria or another contraindication; or presented after enrollment in the trial was already complete. HBeAg denotes hepatitis B e antigen, and TDF tenofovir disoproxil fumarate.